Masako Asayama

1.6k total citations · 1 hit paper
41 papers, 1.0k citations indexed

About

Masako Asayama is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Masako Asayama has authored 41 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Masako Asayama's work include Colorectal Cancer Treatments and Studies (23 papers), Gastric Cancer Management and Outcomes (12 papers) and Cancer Treatment and Pharmacology (9 papers). Masako Asayama is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Gastric Cancer Management and Outcomes (12 papers) and Cancer Treatment and Pharmacology (9 papers). Masako Asayama collaborates with scholars based in Japan, Italy and United States. Masako Asayama's co-authors include Hiroki Hara, Kohei Shitara, Takako Yoshii, Shota Fukuoka, Daisuke Kotani, Akihito Kawazoe, Masashi Wakabayashi, Shogo Nomura, Hitomi Tamura and Takashi Kojima and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Oncology.

In The Last Decade

Masako Asayama

37 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

2020 567 citations Shota Fukuoka, Hiroki Hara et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Masako Asayama

Since Specialization

Citations

This map shows the geographic impact of Masako Asayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masako Asayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masako Asayama more than expected).

Fields of papers citing papers by Masako Asayama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masako Asayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masako Asayama. The network helps show where Masako Asayama may publish in the future.

Co-authorship network of co-authors of Masako Asayama

This figure shows the co-authorship network connecting the top 25 collaborators of Masako Asayama. A scholar is included among the top collaborators of Masako Asayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masako Asayama. Masako Asayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	599TiP PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer 2024 ·Annals of Oncology ·(unknown), Toshiki Masuishi, (unknown), Masako Asayama, (unknown), (unknown), Hiroyuki Takeda, (unknown), (unknown), Hajime Mushiake, Yuta Okumura, (unknown), Masahiro Tajika, (unknown), (unknown), Akira Mishima, Chiho Kudo, Kenta Murotani, Hiroya Taniguchi	0
2	Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018) 2024 ·Journal of Clinical Oncology ·Atsuo Takashima, (unknown), Junki Mizusawa, Fumio Nagashima, Masahiko Ando, Hitoshi Ojima, Tadamichi Denda, Jun Watanabe, Katsunori Shinozaki, Hideo Baba, Masako Asayama, (unknown), Toshiki Masuishi, Ken Nakata, Shunsuke Tsukamoto, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yukihide Kanemitsu, (unknown)	2
3	A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT). 2022 ·Journal of Clinical Oncology ·Tetsuya Hamaguchi, Atsuo Takashima, Junki Mizusawa, Yasuhiro Shimada, Fumio Nagashima, Masahiko Ando, Hitoshi Ojima, Tadamichi Denda, Jun Watanabe, Katsunori Shinozaki, Hideo Baba, Masako Asayama, Tadao Fukushima, Toshiki Masuishi, Ken Nakata, Shunsuke Tsukamoto, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yukihide Kanemitsu	9
4	Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7 2021 ·ESMO Open ·Tsuyoshi Takahashi, Kentaro Yamazaki, Eiji Oki, Manabu Shiozawa, Kenji Mitsugi, Akitaka Makiyama, Michio Nakamura, Hitoshi Ojima, Yoshinori Kagawa, Nobuhisa Matsuhashi, Hiroyuki Okuda, Masako Asayama, Yasuhiro Yuasa, Yoshifumi Shimada, Dai Manaka, Jun Watanabe, Koji Oba, Takayuki Yoshino, Kazuhiro Yoshida, Yoshihiko Maehara	14
5	Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603) 2019 ·Annals of Oncology ·Hiroki Hara, Shota Fukuoka, Naoki Takahashi, Takashi Kojima, Akihito Kawazoe, Masako Asayama, Takako Yoshii, Daisuke Kotani, Hitomi Tamura, Yuichi Mikamoto, (unknown), Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Yosuke Togashi, Hiroyoshi Nishikawa, Kohei Shitara	6
6	Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). 2019 ·Journal of Clinical Oncology ·Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Akihito Kawazoe, Masako Asayama, Takako Yoshii, Daisuke Kotani, Hitomi Tamura, Yuichi Mikamoto, (unknown), Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Yosuke Togashi, Hiroyoshi Nishikawa, Kohei Shitara	59
7	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402) 2018 ·Oncology ·Hiroaki Tanioka, Yuji Miyamoto, Akihito Tsuji, Masako Asayama, Takeshi Shiraishi, Satoshi Yuki, Masahito Kotaka, Akitaka Makiyama, Mototsugu Shimokawa, Takayuki Shimose, Satohiro Masuda, Takuhiro Yamaguchi, Yoshito Komatsu, Hiroshi Saeki, Yasunori Emi, Hideo Baba, Eiji Oki, Yoshihiko Maehara	5
8	REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients 2018 ·Annals of Oncology ·Kohei Shitara, Takeharu Yamanaka, Tadamichi Denda, Yasushi Tsuji, Katsunori Shinozaki, Yoshito Komatsu, (unknown), Junji Furuse, Hiroyuki Okuda, Masako Asayama, Kohei Akiyoshi, Yoshinori Kagawa, Takeshi Kato, Eiji Oki, Takashi Ando, Yasuhiro Hagiwara, Yasuo Ohashi, Takayuki Yoshino	56
9	Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer 2017 ·Journal of Gastrointestinal Surgery ·Akira Ooki, Kiwamu Akagi, Toshimasa Yatsuoka, Masako Asayama, Hiroki Hara, Yoji Nishimura, Hiroshi Katoh, Keishi Yamashita, Masahiko Watanabe, Kensei Yamaguchi	9
10	Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer 2017 ·Oncology Letters ·Yukiya Narita, Shigenori Kadowaki, Toshiki Masuishi, Hiroya Taniguchi, Daisuke Takahari, Takashi Ura, Masashi Ando, Masahiro Tajika, Yasumasa Niwa, Tetsuya Eto, Hiroki Hara, Masako Asayama, Kensei Yamaguchi, Yasushi Yatabe, Kei Muro	9
11	A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma 2017 ·International Journal of Clinical Oncology ·Takahiro Horimatsu, Norisuke Nakayama, Toshikazu Moriwaki, Yoshinori Hirashima, Mikio Fujita, Masako Asayama, Ichiro Moriyama, Koji Nakashima, Eishi Baba, Hiroshi Kitamura, Takao Tamura, Ayumu Hosokawa, Kenichi Yoshimura, Manabu Muto	32
12	A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410) 2017 ·Annals of Oncology ·(unknown), Yasutoshi Kuboki, Eiji Shinozaki, (unknown), (unknown), (unknown), Kensei Yamaguchi, (unknown), (unknown), Masako Asayama, Takahiro Tsushima, Satoshi Hamauchi, (unknown), (unknown), (unknown), (unknown), Akihiro Sato, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino	2
13	Inverse effect of mucinous component on survival in stage III colorectal cancer 2014 ·Journal of Surgical Oncology ·Akira Ooki, Kiwamu Akagi, Toshimasa Yatsuoka, Masako Asayama, Hiroki Hara, Gou Yamamoto, Yoji Nishimura, Kensei Yamaguchi	11
14	Everolimus Dramatically Improves Glycemic Control in Unresectable Metastatic Insulinoma: A Case Report 2013 ·Japanese Journal of Clinical Oncology ·Masako Asayama, (unknown), Hiroki Hara, Akira Ooki, Masafumi Kurosumi, Kensei Yamaguchi	13
15	Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases 2011 ·Cancer Chemotherapy and Pharmacology ·Masako Asayama, Nozomu Fuse, Takayuki Yoshino, Tomonori Yano, Makoto Tahara, Toshihiko Doi, Satoshi Fujii, Atsushi Ohtsu	20
16	Ingesting 500 ml of Polyethylene Glycol Solution During Capsule Endoscopy Improves the Image Quality and Completion Rate to the Cecum 2008 ·Digestive Diseases and Sciences ·Hiroki Endo, Yasuyuki Kondo, Masahiko Inamori, Tomohiko R. Ohya, (unknown), Masako Asayama, Kantaro Hisatomi, Takuma Teratani, Masato Yoneda, Atsushi Nakajima, Nobuyuki Matsuhashi	35
17	Tumorous arteriovenous malformation in the jejunum missed by capsule endoscopy 2008 ·Gastrointestinal Endoscopy ·Hiroki Endo, Nobuyuki Matsuhashi, Masahiko Inamori, Tomohiko R. Ohya, (unknown), Masako Asayama, Kantaro Hisatomi, (unknown), Koji Fujita, Masato Yoneda, Atsushi Nakajima	3
18	Hypoplasia of the right hepatic lobe associated with portal hypertension and idiopathic retroperitoneal fibrosis 2004 ·Journal of Gastroenterology ·Kantaro Hisatomi, Tomohiko R. Ohya, Masako Asayama, Minoru Shibata, Masayoshi Ito, Yukihiro Sakurai, Yuzuru Sato	4
19	A CASE OF LEMMELS SYNDROME TREATED BY EINDOSCOPIC REMOVAL OF AFOOD RESIDUE FROM A DIVERTICULUM 2003 ·Acta gastro-enterologica belgica ·(unknown), Yukihiro Sakurai, (unknown), (unknown), (unknown), Masako Asayama, (unknown), (unknown), Masayoshi Ito, Yuzuru Sato	0
20	Acute Hepatitis Outbreak in Tokyo Caused by Hepatitis A Virus of Common Origin Transmitted through Oral and Sexual Routes 2000 ·Japanese Journal of Infectious Diseases ·(unknown), Hiroyuki Oka, Masako Asayama, (unknown), Hiroko Yamashita, Natsuo Tachikawa, Junichi Akiyama, Akira Yasuoka, Shinichi Oka, Shigeru Yamato, (unknown), (unknown), Naohiko Masaki, Kei Matsueda, (unknown), Shigeki Hayashi	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact